Role of (chemo)-radiotherapy in resectable gastric cancer

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 541-550

  Foo, M ^a   Crosby, T ^b   Rackley, T ^b   Leong, T ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer; Chemoradiation; Chemoradiotherapy; Gastric; Radiotherapy; Stomach

Indexed keywords

ANTINEOPLASTIC AGENT; INT 0116; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; GASTRECTOMY; HUMAN; IRRADIATION; LYMPH NODE; LYMPH NODE DISSECTION; PRIORITY JOURNAL; STOMACH CANCER; SURGICAL ANATOMY; ADJUVANT THERAPY; PROGNOSIS; STOMACH NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; HUMANS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 84905565671     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.06.004     Document Type: Article

References (63)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon: International Agency for Research on Cancer, 2010.
2. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. American Joint Committee on Cancer staging manual 2010, 117-126. Springer, New York. 7th ed.
3. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
4. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730.
5. Greene F.L., Page D., Fleming I., et al. American Joint Committee on Cancer staging manual 2002, 99-106. Springer, New York. 6th ed.
6. Wu C.W., Hsiung C., Lo S.S., Hsieh M.C., Shia L.T., Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004, 91(3):283-287.
7. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79(9-10):1522-1530.
8. Dent D.M., Madden M.V., Price S.K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988, 75(2):110-112.
9. Songun I., Putter H., Kranenbarg E.M.-K., Sasako M., van de Velde C.J.H. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11(5):439-449.
10. Degiuli M., Sasako M., Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010, 97(5):643-649.
11. Lustosa S.S., Ii H.S., Nagib Á., et al. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras 2008, 23(6):520-530.
12. Tanizawa Y., Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer 2010, 13(3):137-148.
13. McCulloch P., Nita M.E., Kazi H., Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003, (4):CD001964.
14. Wisbeck W.M., Becher E.M., Russell A.H. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol 1986, 7(1):13-18.
15. Gunderson L.L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol 1982, 8(1):1-11.
16. Gunderson L.L. Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol 2002, 12(2):150-161.
17. Skoropad V.Y., Berdov B.A., Mardynski Y.S., Titova L.N. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 2000, 26(8):773-779.
18. Allum W., Hallissey M., Ward L., Hockey M. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br J Cancer 1989, 60(5):739-744.
19. Dent D., Werner I., Novis B., Cheverton P., Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979, 44(2):385-391.
20. Moertel C.G., Childs D.S., O'Fallon J.R., Holbrook M.A., Schutt A.J., Reitemeier R.J. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984, 2(11):1249-1254.
21. Smalley S.R., Benedetti J.K., Haller D.G., et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012, 30(19):2327-2333.
22. Ajani J.A., Bentrem D.J., Besh S., et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013, 11(5):531-546.
23. Okines A., Verheij M., Allum W., Cunningham D., Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v50-54.
24. Knight G., Earle C.C., Cosby R., et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer 2013, 16:28-40.
25. Macdonald J.S. Gastric cancer: Nagoya is not New York. J Clin Oncol 2011, 29(33):4348-4350.
26. Ohri N., Garg M.K., Aparo S., et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2013, 86(2):330-335.
27. Fiorica F., Cartei F., Enea M., et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007, 33(8):729-740.
28. Valentini V., Cellini F., Minsky B.D., et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 2009, 92(2):176-183.
29. Guo L., Wang X., Ma B., et al. Radiotherapy combined with surgical treatment for gastric cancer: a meta-analysis. Chinese-German J Clin Oncol 2011, 10(8):442-449.
30. Lee J., Lim D.H., Kim S., et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012, 30(3):268-273.
31. Zhu W., Xua D., Pu J., et al. Phase III randomised trial. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012, 104(3):361-366.
32. Kim T.H., Park S.R., Ryu K.W., et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012, 84(5):e585-592.
33. Bamias A., Karina M., Papakostas P., et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010, 65(6):1009-1021.
34. Kwon H.-C., Kim M.C., Kim K.H., et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 2010, 6(4):278-285.
35. Yu C., Yu R., Zhu W., Song Y., Li T. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012, 138(2):255-259.
36. Shridhar R., Dombi G.W., Weber J., Hoffe S.E., Meredith K., Konski A. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol 2012, 35(3):216-221.
37. Fuchs C.S., Tepper J.E., Niedzwiecki D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CR. J Clin Oncol 2011, 29(15 Suppl.):4003.
38. Smalley S.R., Gunderson L., Tepper J., et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002, 52(2):283-293.
39. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011, 14(2):101-112.
40. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011, 14(2):113-123.
41. Leong T., Joon D.L., Willis D., et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2011, 79(3):690-695.
42. Jansen E.P.M., Nijkamp J., Gubanski M., Lind P.A.R.M., Verheij M. Interobserver variation of clinical target volume delineation in gastric cancer. Int J Radiat Oncol Biol Phys 2010, 77(4):1166-1170.
43. Ohri N., Shen X., Dicker A.P., Doyle L.A., Harrison A.S., Showalter T.N. Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013, 105(6):387-393.
44. Peters L.J., O'Sullivan B., Giralt J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010, 28(18):2996-3001.
45. Leong T., Willis D., Joon D.L., Condron S., Hui A., Ngan S.Y.K. 3D conformal radiotherapy for gastric cancer - results of a comparative planning study. Radiother Oncol 2005, 74(3):301-306.
46. Minn A.Y., Hsu A., La T., et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116(16):3943-3952.
47. Chakravarty T., Crane C.H., Ajani J.A., et al. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2012, 83(2):581-586.
48. Dahele M., Skinner M., Schultz B., Cardoso M., Bell C., Ung Y.C. Adjuvant radiotherapy for gastric cancer: a dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans. Med Dosim 2010, 35(2):115-121.
49. Morganti A.G., Di Castelnuovo A., Massaccesi M., et al. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. Br J Radiol 2013, 86(1029):20130274.
50. Wysocka B., Kassam Z., Lockwood G., et al. Interfraction and respiratory organ motion during conformal radiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2010, 77(1):53-59.
51. Pan C.C., Kavanagh B.D., Dawson L.A., et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S94-100.
52. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
53. Milano M.T., Constine L.S., Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007, 17(2):131-140.
54. Dawson L.A., Kavanagh B.D., Paulino A.C., et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S108-S115.
55. Leong T., Smithers M., Michael M., et al. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J Clin Oncol 2012, 30(15 Suppl.):TPS4141.
56. Dikken J.L., van Sandick J.W., Maurits Swellengrebel H.A., et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011, 11(1):329.
57. O'Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002, 359(9325):2235-2241.
58. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740.
59. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373(9666):811-820.
60. Zhang Z.X., Gu X.Z., Yin W.B., Huang G.J., Zhang D.W., Zhang R.G. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys 1998, 42(5):929-934.
61. Ajani J.A., Mansfield P.F., Janjan N., et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004, 22(14):2774-2780.
62. Ajani J.A., Mansfield P.F., Crane C.H., et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23(6):1237-1244.
63. Ajani J.A., Winter K., Okawara G.S., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006, 24(24):3953-3958.